US Federal 2025-2026 Regular Session

US Federal Senate Bill SB2513

Introduced

7/29/25

Refer

7/29/25

Caption

OTC Monograph Drug User Fee Transparency Act

Latest US SB2513 Activity

View All Events: US 2025-2026 Regular Session SB2513

Companion Bills

No companion bills found.

Previously Filed As

US SB2292

Over-the-Counter Monograph Drug User Fee Amendments

US HB4273

Over-the-Counter Monograph Drug User Fee Amendments

US HB5371

Continuing Appropriations Act, 2026 Legislative Branch Appropriations Act, 2026 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2026 Over-the-Counter Monograph Drug User Fee Amendments

US HB8339

Drug Origin Transparency Act of 2026

US HB1843

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

US HB7050

Homeopathic Drug Product Safety, Quality, and Transparency Act

US SB229

DTC Act of 2025 Drug-price Transparency for Consumers Act of 2025

US HB3789

DTC Act of 2025 Drug-price Transparency for Consumers Act of 2025

US HB6868

ACCESS Through OTC Innovation Act Advancing Consumer Choice, Equity, Safety, and Self-Care Through OTC Innovation Act

US SB1302

Increasing Transparency in Generic Drug Applications Act

Similar Bills

US SB2292

Over-the-Counter Monograph Drug User Fee Amendments

US HB4273

Over-the-Counter Monograph Drug User Fee Amendments

FL S0560

Chemical Additives in Food Products

MS SB2544

Mississippi Active Pharmaceutical Ingredient Quality Assurance Act; enact to impose certain provisions for compounding.

CA AB1990

Pharmacy Law: compounded medications: consumer protection.

US HB6868

ACCESS Through OTC Innovation Act Advancing Consumer Choice, Equity, Safety, and Self-Care Through OTC Innovation Act

GA HB1361

Pharmacies; compounding of certain active pharmaceutical ingredients; provisions

AZ HB4036

bulk drug substances; prohibitions